BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

– Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across 12-month period – – Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across 12-month period –

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates from its drug discovery process and additional therapies from its pipeline that the company will highlight at a Research and Development (R&D) Day today at 1:00p ET at the company's Discovery Center of Excellence in Birmingham, Alabama. A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com.

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue -

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place at the Anaheim Convention Center in Anaheim, Calif., from November 9-13, 2023.

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November 3, 2023, where the company plans to describe its drug discovery process and introduce additional therapies from its pipeline.

BioCryst to Host R&D Day on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, November 2, 2023.

BioCryst to Report Third Quarter 2023 Financial Results on November 2

BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for the reimbursement of its Orladeyo drug for the prevention of hereditary angioedema (HAE) attacks in adults and patients 12 years or older in Quebec. By 10:30am ET, the company's shares were 6.5% higher at $7.30.

BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment

RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for PrORLADEYO® (berotralstat) to be reimbursed for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age and older in Quebec.

INESSS Recommends Public Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Agenus

Nano-X Imaging

Growth stocks have slumped in August. This broad sell-off has created some compelling buying opportunities.

3 Magnificent Growth Stocks to Buy on the Dip

Spotify

Biogen

Bank of New York Mellon

Harley-Davidson

Quaker Chemical

Lazard

Scotts Miracle-Gro

TreeHouse Foods

United Continental Hlds

Barron's looked at stocks in the Russell 3000 that have done little for the past five years and identified 10 stocks where improving analyst sentiment could signal better days ahead.

Harley, Spotify, and 8 Other Dead Money Stocks That Are Poised to Come Alive

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Stacy Ku - Cowen & Co. Jon Wolleben - JMP Securities Justin Kim - Oppenheimer & Co. Inc. Serge Belanger - Needham & Company Operator Good morning and welcome to the BioCryst Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript

— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS of ($0.40), non-GAAP EPS of ($0.24), excluding one-time debt extinguishment fee of $29 million— — BCX10013, once-daily, oral Factor D inhibitor, clinical trial in patients expected to begin enrollment by end of year— —Company to host R&D day on Friday, November 3 rd to introduce additional pipeline assets and programs— RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

The average of price targets set by Wall Street analysts indicates a potential upside of 107.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a Bet

RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, August 3, 2023.

BioCryst to Report Second Quarter 2023 Financial Results on August 3

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO® (berotralstat) in Turkey.

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:30 p.m. ET in New York.

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) congress which is being held in Hamburg, Germany from June 9 – 11, 2023.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its main growth driver, Orladeyo.

Why BioCryst Pharmaceuticals Stock Is Soaring Today

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Allison Bratzel - Piper Sandler Jon Wolleben - JMP Securities Tazeen Ahmad - Bank of America Stacy Ku - Cowen & Co. Justin Kim - Oppenheimer & Co. Inc. Serge Belanger - Needham & Company Liisa Bayko - Evercore ISI Brian Abrahams - RBC Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies, LLC Operator Good morning and welcome to the BioCryst Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2023 Earnings Call Transcript

—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth q-o-q— —Over 1,000 U.S. patients on ORLADEYO therapy— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— RESEARCH TRIANGLE PARK, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

News for BioCryst Pharmaceuticals Stock (BCRX)